Nanobodies — also known as VHH antibodies or single-domain antibodies — are the smallest functional antigen-binding fragments derived from the heavy-chain-only antibodies naturally found in camelids such as llamas, alpacas, and camels. With a molecular weight of approximately 12–15 kDa, they are roughly ten times smaller than conventional IgG antibodies, yet retain exceptional binding affinity and specificity for their targets.
In the context of drug discovery, custom nanobodies offer a transformative toolkit. Their compact size enables access to cryptic epitopes — binding sites that are sterically inaccessible to conventional antibodies — opening entirely new avenues for targeting GPCRs, ion channels, viral proteins, and other challenging membrane-associated drug targets. Their high thermal stability, solubility in aqueous conditions, and compatibility with microbial expression systems further reduce development costs and timelines.
The global nanobody therapeutics market was valued at over USD 1.2 billion in 2023 and is projected to surpass USD 5.8 billion by 2032, driven by a surge in oncology, immunology, and infectious disease programs. Custom nanobody generation — tailored to specific research targets, species, and application requirements — has become a cornerstone of both academic drug discovery pipelines and pharmaceutical R&D operations worldwide.
Over 40 nanobody-based therapeutics are currently in clinical trials globally, spanning oncology, autoimmune diseases, and rare genetic disorders. Caplacizumab (Cablivi®) — the first approved nanobody drug — has validated the platform commercially, spurring major pharma investments in VHH-based biologics.
Contract research organizations (CROs) offering custom nanobody services have grown 3× in the past five years. The ability to deliver fully characterized, high-affinity nanobodies within 10–14 weeks — from immunization to sequencing — has made CRO-based nanobody discovery the preferred model for biotech startups and large pharma alike.
Machine learning models trained on VHH sequence-structure databases are now being used to predict binding affinity, optimize CDR loops, and design synthetic nanobody libraries in silico. This AI-driven approach reduces library screening iterations and dramatically shortens the path from target identification to lead candidate selection.
The modular nature of nanobodies makes them ideal building blocks for bispecific and multispecific constructs. Tandem VHH formats targeting dual tumor antigens, or VHH-Fc fusions combining effector function with tumor targeting, represent one of the fastest-growing segments in the antibody engineering market.
Beyond therapeutics, custom nanobodies are transforming in vitro diagnostics. Their small size enables dense surface immobilization on biosensor chips, lateral flow strips, and ELISA plates — delivering unprecedented sensitivity for pathogen detection, biomarker quantification, and point-of-care testing platforms.
Leading life science companies are establishing co-development partnerships with academic nanobody discovery labs and specialized CROs. These collaborations — structured around milestone-based licensing, co-IP agreements, and shared data platforms — are accelerating the translation of nanobody hits into clinical candidates at unprecedented speed.
Our team of experienced scientists works closely with customers to design and execute tailored strategies for nanobody discovery, ensuring the generation of high-quality leads that align with project goals.
Antibody humanization from a broad range of parental species including mouse, rat, rabbit, llama, and avian — essential for reducing immunogenicity in therapeutic applications.
Our Membrane Proteomics platform offers comprehensive identification, quantification, and characterization of membrane proteins — key drug targets including GPCRs, ion channels, and transporters.
Alpha Lifetech offers native antibody libraries (scFv, Fab, VHH formats and customized) from host animals like Goat, Camel, and Llama — ideal for high-throughput drug candidate screening.
Custom nanobodies serve as crystallization chaperones for membrane proteins and GPCRs, stabilizing conformational states that are otherwise impossible to capture by X-ray crystallography or cryo-EM. This enables high-resolution structural insights that directly inform rational drug design and fragment-based lead optimization.
In drug screening campaigns, nanobodies are deployed as surrogate ligands, blocking antibodies, or reporter fusion proteins in cell-based assays. Their small size minimizes steric interference, while their high stability ensures reproducible assay performance across large compound library screens.
Unlike conventional antibodies, nanobodies can be expressed intracellularly as "intrabodies" to modulate cytoplasmic targets — transcription factors, kinases, and oncoproteins — previously considered undruggable. This opens entirely new therapeutic modalities for cancer and neurodegenerative diseases.
Analogous to antibody-drug conjugates (ADCs), nanobody-drug conjugates leverage the superior tumor penetration and rapid clearance kinetics of VHHs to deliver cytotoxic payloads with high precision. Their smaller size improves solid tumor penetration by 3–5× compared to full-length IgG conjugates.
Custom nanobodies targeting transferrin receptor (TfR) or LRP1 are being engineered as BBB-crossing shuttles to deliver therapeutic payloads into the CNS — a major unmet need in Alzheimer's, Parkinson's, and glioblastoma drug development programs.
Radiolabeled or fluorescently tagged custom nanobodies enable PET imaging and near-infrared optical imaging of tumor antigens in vivo, providing companion diagnostic tools for patient stratification and real-time monitoring of therapeutic response — a critical component of precision oncology pipelines.
Alpha Lifetech Inc. was founded by a group of scientists with extensive experience in membrane protein production, nanobody discovery, monoclonal development, and other pharmaceutical pre-development services. Based on our several technology service platforms, Alpha Lifetech Inc. has launched nearly 10,000 high-quality spot membrane protein reagents, cytokines, drug target antibodies and other related reagents. Whether you're working in the fields of immunology, cell biology, molecular biology, or any other scientific discipline, Alpha Lifetech's comprehensive range of research products will help you achieve accurate and reliable results. We pride ourselves on being able to offer a comprehensive set of high-quality products and services tailored to customer needs, which help advance the projects of scientific research institutions, academics, and enterprises in the life science industry.
Alpha Lifetech Inc. is committed to providing the highest level of customer services, competitive pricing, speedy delivery, and a comprehensive, cutting-edge product offering. Our sales and technical support staff are available to help you select the right products and service solutions. As a reliable supplier and partner, Alpha Lifetech Inc. always puts customers first. We cherish every opportunity to collaborate with worldwide customers in scientific exploration. Welcome to contact our technical support at any time.
Alpha Lifetech Inc. provides a wide range of technology platforms, including membrane protein, antibody discovery, single B cell sorting, and hybridoma technology. Whether you're engaged in immunology, cell biology, molecular biology, or any other scientific discipline, our comprehensive suite of services is designed to empower you with precise and dependable results.
Custom nanobodies provide unparalleled flexibility in format, species, and application. From target validation through lead optimization to preclinical candidate selection, a purpose-built nanobody — designed around your specific antigen, assay requirements, and therapeutic modality — delivers faster timelines, higher hit rates, and lower development risk than off-the-shelf antibody solutions. Partner with Alpha Lifetech to access the full spectrum of custom VHH discovery, engineering, and characterization capabilities under one roof.
Our platform utilizes phage and yeast display technology to develop different forms of antibodies: VHH single domain antibodies, Fab antibodies, and scFv antibodies, resulting in high affinity and high specificity antibodies. This platform is the cornerstone of our custom nanobody drug discovery offering, enabling rapid identification of leads against even the most challenging drug targets.
READ MORE
VHH Antibody Discovery Service
View Details
Fab Antibody Discovery Service
View Details
ScFv Antibody Discovery Service
View Details
Phage Display System
View Details
Phage Library Construction Service
View Details
The aptamer platform provided by Alpha Lifetech includes two categories: aptamer synthesis platform, which mainly involves SELEX aptamer library synthesis service and aptamer development service, and aptamer screening platform including screening services based on SELEX technology for proteins, peptides, cells, small molecules, and other target molecules, as well as aptamer optimization and identification analysis services.
READ MORE
Aptamer Synthesis Platform
View Details
Aptamer Screening Platform
View Details
Aptamer Optimization Service
View Details
Aptamer Analysis Service
View Details
Aptamer Research Service
View Details
Our monoclonal antibody development services include three technologies: phage display technology, single-B cell technology, and hybridoma cell technology, which produce monoclonal antibodies for different species. These technologies are directly applicable to custom nanobody drug discovery programs requiring high-specificity lead candidates.
READ MORE
Single B Cell Sorting Platform
View Details
Hybridoma Technology Platform
View Details
Phage Display Technology Platform
View Details
Mouse mAb Development Service
View Details
Rabbit mAb Development Service
View Details
We also provide a series of technical services related to antibody engineering, stable cell line construction, yeast display, protein interaction analysis, etc., laying the foundation for antibody development. These enabling technologies are critical for custom nanobody drug discovery workflows requiring rigorous characterization and optimization of lead candidates.
READ MORE
Stable Cell Line Construction Service
View Details
Animal Immunization Platform
View Details
Protein Interaction Service
View Details
Yeast Display Library Construction
View Details
Yeast Display Library Screening
View DetailsExceptional Nanobody discovery capabilities from Alpha Lifetech. Their team's dedication to customer satisfaction and scientific excellence is evident in every interaction. Grateful for their partnership and looking forward to future collaborations!
— Riley HarperQuality products! Our experience with Alpha Lifetech has been nothing short of outstanding. The custom nanobodies they developed for our drug discovery program exceeded all our affinity and selectivity benchmarks.
— Stella GrantReliable, responsive, and results-driven — Alpha Lifetech. Their ability to deliver high-quality custom nanobodies on tight timelines has been a game-changer for our preclinical drug discovery pipeline.
— Olivia WestSimply put, Alpha Lifetech delivers. Their dedication to customer satisfaction and quality service is unmatched, and we're grateful to have them as a trusted partner in our nanobody-based drug discovery programs.
— Ava MitchellThe membrane protein expression and nanobody discovery services from Alpha Lifetech have been instrumental in our GPCR drug discovery efforts. Highly professional team with deep technical expertise.
— Dr. James ThorntonAlpha Lifetech's custom VHH library construction and phage display screening capabilities are world-class. They helped us identify a highly specific nanobody lead against a previously undruggable target within 12 weeks.
— Dr. Sarah Chen
Custom VHH nanobody generation from camelid immunization through library screening and lead characterization for drug discovery applications.
High-affinity Fab fragment discovery using phage display and yeast display platforms, optimized for drug target engagement and functional blocking.
Single-chain variable fragment discovery and optimization for bispecific constructs, CAR-T cell therapy, and intrabody drug discovery programs.
Comprehensive phage display platform enabling high-throughput screening of diverse antibody libraries against drug targets with exceptional hit rates.
Custom phage display library construction with diversity exceeding 10¹⁰ clones, optimized for drug target-specific nanobody and antibody fragment discovery.
SELEX-based aptamer synthesis and development services targeting proteins, peptides, cells, and small molecules relevant to drug discovery programs.
FACS-based single B cell isolation and antibody cloning from immunized animals, enabling direct access to native antibody sequences for drug discovery.
Yeast surface display library construction and screening for affinity maturation and engineering of custom nanobody drug candidates with improved potency.